Stelara biosimilars comparison
BiosimilarsCompare Stelara (ustekinumab) biosimilars to the reference product. Stelara biosimilars offer the same efficacy for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis at potentially lower cost. Multiple biosimilars are now FDA-approved.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Stelara (reference) | Janssen | SC injection / IV infusion | Every 8–12 weeks (SC); single IV induction for IBD | Original reference product; extensive long-term safety data |
| Wezlana (ustekinumab-auub) | Amgen | SC injection / IV infusion | Same as reference | First FDA-approved Stelara biosimilar; interchangeable |
| Pyzchiva (ustekinumab-ttwe) | Samsung Bioepis | SC injection / IV infusion | Same as reference | FDA-approved biosimilar; interchangeable designation |
| Otulfi (ustekinumab-arhi) | Fresenius Kabi | SC injection / IV infusion | Same as reference | FDA-approved biosimilar |
| Imuldosa (ustekinumab-aekn) | Celltrion | SC injection / IV infusion | Same as reference | FDA-approved biosimilar |
| Selarsdi (ustekinumab-sbir) | Sandoz | SC injection / IV infusion | Same as reference | FDA-approved biosimilar from Sandoz |
| Pyzchiva (ustekinumab-ttwe): 2nd entry | Biocon | SC injection / IV infusion | Same as reference | Additional manufacturer for expanded supply |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.